RecruitingEarly Phase 1NCT07341360

Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei

Studying Pseudomyxoma peritonei

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Oslo University Hospital
Intervention
Pseudovax(other)
Enrollment
10 target
Eligibility
18 years · All sexes
Timeline
20252034

Study locations (1)

Collaborators

BeiGene

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07341360 on ClinicalTrials.gov

Other trials for Pseudomyxoma peritonei

Additional recruiting or active studies for the same condition.

See all trials for Pseudomyxoma peritonei

← Back to all trials